| Kaitlyn Oaks, APRN | |
|
703 N Dupont Blvd, Milford, DE 19963-1003 | |
| (302) 422-4559 | |
| Not Available |
| Full Name | Kaitlyn Oaks |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 703 N Dupont Blvd, Milford, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013541986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | LJ-0000377 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kaitlyn Oaks, APRN Po Box 191, Rockland, DE 19732-0191 Ph: () - | Kaitlyn Oaks, APRN 703 N Dupont Blvd, Milford, DE 19963-1003 Ph: (302) 422-4559 |
News Archive
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.
DGIMED ORTHO, Inc. announced today that the company has received notification of clearance of its 510(k) submission for the DISTALOCKTM Titanium Femoral Intramedullary Nail system. In November 2009, the Company also received its initial clearance on the DISTALOCKTM Drill system with a stainless steel femoral IM nail.
› Verified 3 days ago
Ms. Jolynn Solomon, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 302-422-3311 | |
Mrs. Jolene M. Dickerson, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Nemours Pediatrics Milford, 703 N. Dupont Highway, Milford, DE 19963 Phone: 302-422-4559 Fax: 302-422-4082 | |
Emily Heishman, FNP-C, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1197 Airport Rd, Milford, DE 19963 Phone: 302-508-0541 Fax: 302-202-5779 | |
Toccara Renee Barber, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 21 W Clarke Ave, Milford, DE 19963 Phone: 320-503-7650 | |
Tricia L Delnay, ACNP-BC, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 101 Wellness Way Ste 300, Milford, DE 19963 Phone: 302-422-6050 Fax: 302-422-6685 | |
Carla Hull, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 100 Kings Hwy, Milford, DE 19963 Phone: 302-503-3922 |